Skip to main content
ETON
NASDAQ Life Sciences

Eton Pharmaceuticals Adds Orphan Drug IMPAVIDO® to Rare Disease Portfolio via U.S. Commercialization Deal

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$32.89
Mkt Cap
$900.935M
52W Low
$13.085
52W High
$33.41
52W Position info
151% above low
Off High info
1.6% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

ETON has more than doubled off its 52-week low of $13.085.

Summary

Eton Pharmaceuticals has secured U.S. commercialization rights for IMPAVIDO® (miltefosine), an orphan drug indicated for the treatment of leishmaniasis, through a supply and distribution agreement with an affiliate of Knight Therapeutics. This move expands Eton's rare disease portfolio, aligning with its stated strategy to grow through product launches and acquisitions. The company recently reported strong Q1 2026 results, with a 73% increase in product sales driven by its expanded portfolio, and this agreement represents another step in that growth trajectory. While specific financial terms were not disclosed, adding a commercially available, life-saving medication reinforces Eton's focus on specialized patient populations and could contribute to future revenue streams. Traders will monitor the financial impact of this agreement in upcoming earnings reports.

At the time of this announcement, ETON was trading at $32.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $900.9M. The 52-week trading range was $13.09 to $33.41. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ETON - Latest Insights

ETON
Nov 06, 2026, 9:04 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $58.86
Real-time Price: $60.85 info
Change: +$1.99 (+3%) info
Market Cap: $1.755B info
ETON
Nov 05, 2026, 4:32 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $57.90
Real-time Price: $60.85 info
Change: +$2.95 (+5%) info
Market Cap: $1.755B info
ETON
Nov 05, 2026, 4:13 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $56.06
Real-time Price: $60.85 info
Change: +$4.79 (+9%) info
Market Cap: $1.755B info
ETON
Nov 05, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $47.15
Real-time Price: $60.85 info
Change: +$13.70 (+29%) info
Market Cap: $1.755B info
ETON
Nov 05, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $47.15
Real-time Price: $60.85 info
Change: +$13.70 (+29%) info
Market Cap: $1.755B info